Publicaciones en colaboración con investigadores/as de French Institute of Health and Medical Research (18)

2022

  1. TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: An international performance evaluation study

    Journal of Clinical Pathology, Vol. 75, Núm. 6, pp. 416-421

  2. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219

2019

  1. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma

    Oncotarget, Vol. 9, Núm. 87, pp. 35726-35741

2016

  1. ΔNp63α silences a miRNA program to aberrantly initiate a wound-healing program that promotes TGFβ-induced metastasis

    Cancer Research, Vol. 76, Núm. 11, pp. 3236-3251

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  2. α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects

    Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1851, Núm. 3, pp. 273-281

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

2013

  1. ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo

    Gene, Vol. 521, Núm. 1, pp. 55-61

  2. FHL2 Silencing Reduces Wnt Signaling and Osteosarcoma Tumorigenesis In Vitro and In Vivo

    PLoS ONE, Vol. 8, Núm. 1

  3. Zinc chelation: A metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance

    Cell Death and Disease, Vol. 4, Núm. 10

2012

  1. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort

    European Respiratory Journal, Vol. 40, Núm. 1, pp. 177-184

  2. Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development

    Lung Cancer, Vol. 75, Núm. 2, pp. 156-160

2011

  1. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis

    Journal of Bone and Mineral Research, Vol. 26, Núm. 7, pp. 1533-1542

  2. Identifying polyglutamine protein species in situ that best predict neurodegeneration

    Nature Chemical Biology, Vol. 7, Núm. 12, pp. 925-934

2010

  1. Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: The European Early Lung Cancer Project

    International Journal of Oncology, Vol. 37, Núm. 2, pp. 455-461

2009

  1. EUELC project: A multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration

    European Respiratory Journal, Vol. 34, Núm. 6, pp. 1477-1486